Clinical trials: Small Cell Carcinoma of Lung
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
- Trial name
- NCT07164313
- Testing
- ZW251
- Where
- 25 sites in United States, Ireland and 4 more
- Volunteers
- 140 people
- Sponsor
- Zymeworks BC Inc.
EGFR-mutant Non-Small Cell Lung Cancer
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC
The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.
- Trial name
- NCT03904823
- Testing
- famitinib po, HS-10296 po
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Lung Neoplasms, Myeloid-Derived Suppressor Cells
Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms.
- Conditions
- Lung Neoplasms, Myeloid-Derived Suppressor Cells, Immunosuppression
- Trial name
- MyéloLungSC (NCT06024226)
- Testing
- Tumor samples
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bordeaux
Non-Small Cell Lung Cancer, Stage IIIB or IV
Alimta and Gemcitabine in Non-Small Cell Lung Cancer
The aims of this study are: (1) to assess the safety and activity of gemcitabine plus Alimta (pemetrexed) regimen (GA regimen) in patients with advanced NSCLC patients in the context of a randomized trial, and (2) to compare the…
- Trial name
- ANGEL (NCT00434135)
- Testing
- gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Southern Italy Cooperative Oncology Group
Non Small Cell Lung Cancer
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC
- Trial name
- NCT06082635
- Testing
- TGRX-326, Crizotinib
- Where
- China
- Volunteers
- 321 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Non Small Cell Lung Cancer
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer.
- Trial name
- NCT00890825
- Testing
- AZD6244, docetaxel
- Where
- 63 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
After the second-line treatment of patients with non-T790M mutations, chemotherapy with platinum-containing drugs was used, and chemotherapy-related toxicity was high.
- Trial name
- NCT03766490
- Testing
- Anlotinib Hydrochloride, Gefitinib, Icotinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Advanced Solid Tumors Cancer
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when…
- Trial name
- NCT02988960
- Testing
- ABBV-927, ABBV-181
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 163 people
- Sponsor
- AbbVie
Non-small Cell Lung Cancer(NSCLC), EGFR Mutant
A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy
Lazertinib is currently approved as a first-line treatment for EGFR-mutant NSCLC in South Korea. However, many patients experience peripheral neuropathy, which causes severe numbness, tingling, or painful muscle cramps.
- Trial name
- NCT07774520
- Testing
- Supplementation of magnesium lactate, Dose reduction of lezertinib
- Where
- South Korea
- Volunteers
- 1,173 people
- Sponsor
- Samsung Medical Center
Lung Cancer Stage II, Lung Cancer Stage III
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and treated with Stereotactic Body Radiation Therapy (SBRT) followed by concurrent…
- Conditions
- Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
- Trial name
- NCT03141359
- Testing
- SBRT, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Wake Forest University Health Sciences
Small Cell Carcinoma
Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma
This phase I trial studies the side effects and best dose of nortriptyline hydrochloride when given together with paclitaxel in treating patients with small cell carcinoma that has come back.
- Trial name
- NCT02881125
- Testing
- Nortriptyline Hydrochloride, Paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Non-Small Cell Lung Cancer
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
Non-Small Cell Lung Cancer (NSCLC) is one of the deadliest types of cancer. In lung cancer patients with a tumor that can be removed by surgery, adjuvant chemotherapy increases survival.
- Trial name
- NCT05911308
- Testing
- Durvalumab, Carboplatin, Abequolixron
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer
Immune Boost In Non-Small Cell Lung Cancer
Insufficient migration and activation of tumour specific effector T cells seems to be the one important reason for inadequate host anti-tumour immune response. Ionizing radiation can induce a variety of immune responses.
- Trial name
- RadImmune (NCT02319408)
- Testing
- Preoperative radiation
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- University Hospital Heidelberg
Carcinoma, Non-Small-Cell Lung
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of compromised tissue to deliver sufficient dose to the tumor while…
- Trial name
- NCT05302817
- Testing
- Hyperpolarized xenon MRI
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Xemed LLC
Melanoma, Non Small Cell Lung Cancer
Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression
Exploratory interventional study of prognostic serum biomarkers of cancer progression. Study of the relationship between the blood levels of soluble PDL1 and β2-microglobulin, and the clinical course of a metastatic solid tumor…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Renal Cancer
- Trial name
- Onco-PDL1s/B2M (NCT05426317)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Advanced Solid Tumours, Non-small Cell Lung Cancer
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
Eligible subjects will be allocated to one of four cohorts based on tumour type and presence of specific biomarker. Subjects will receive open-label Dacomitinib as tablets for oral administration on a continuous daily basis at a…
- Conditions
- Advanced Solid Tumours, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04946968
- Testing
- Oral Dacomitinib
- Where
- 2 sites in Singapore
- Volunteers
- 24 people
- Sponsor
- National Cancer Centre, Singapore
NSCLC
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
This study was a parallel, randomized, multicenter phase II clinical trial to evaluate the efficacy and safety of TY-9591 combined with platinum-based chemotherapy as first-line treatment in patients with locally advanced or…
- Trial name
- NCT06672068
- Testing
- TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin, TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin
- Volunteers
- 60 people
- Sponsor
- TYK Medicines, Inc
Resectable Clinical Stage IB to III NSCLC
Prospective Observational Study of Baseline Tumor Genomic Profiling and Circulating Tumor DNA in Neoadjuvant Chemoimmunotherapy for Stage IB-III Non-Small Cell Lung Cancer
The goal of this observational study is to learn whether tests on tumor tissue and blood can predict how well patients with stage IB-III non-small cell lung cancer respond to chemotherapy combined with immunotherapy given before…
- Trial name
- NCT06907160
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Lung Cancer
SABR for T1-2a N1 NSCLC
Conventionally fractionated radiation therapy given over 6-7 weeks alone, sequentially, or concurrent with chemotherapy have produced poor outcomes in Stage II NSCLC in most series.
- Trial name
- NCT03321760
- Testing
- Stereotactic Ablative Radiation Therapy (SABR)
- Where
- 3 sites in United States
- Sponsor
- Indiana University
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.